aspirin has been researched along with Complications, Hematologic Pregnancy in 168 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts." | 9.14 | Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. ( Barrett, J; Clark, CA; Crowther, MR; Gent, M; Ginsberg, JS; Hawker, GA; Kingdom, JC; Laskin, CA; Spitzer, KA, 2009) |
| "Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants." | 9.12 | Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021) |
| "Aspirin and heparin are widely used as preventive strategy to reduce the high risk of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL)." | 9.05 | Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. ( Goddijn, M; Hamulyák, EN; Marijnen, MC; Middeldorp, S; Scheres, LJ, 2020) |
| "To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone." | 8.93 | Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia." | 8.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without apparent causes other than inherited thrombophilia." | 8.85 | Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. ( Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2009) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 8.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 7.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| " During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section." | 7.73 | [Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005) |
| "Live birth rates are increased by treatment with heparin and aspirin in cases of poor pregnancy outcome such as antiphospholipid syndrome." | 7.73 | Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. ( Black, S; Bose, P; Huppertz, B; Kadyrov, M; Neulen, J; Regan, L; Weissenborn, U, 2005) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 7.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| "To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation." | 7.68 | Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993) |
| "Aspirin was shown to increase oxygen affinity of hemoglobin via acetylating lysine residues and its general acetylating activity on proteins such as histones makes it also an interesting candidate to activate fetal hemoglobin." | 5.34 | Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. ( Altinoz, MA; Carin, MN; Gedikoglu, G; Ozdilli, K, 2007) |
| "Essential thrombocythemia is a rare disease of unknown origin characterized by abnormal increase in the platelet count." | 5.32 | Pregnancy in essential thrombocythemia during aspirin treatment. ( Cannata, ML; Corrado, F; Ruggeri, Z; Stella, NC, 2003) |
| "Screening results for thrombophilia and antithrombotic treatment with enoxaparin, aspirin, or both and pregnancy outcomes." | 5.27 | The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. ( Elias, A; Elias, M; Nahas, R; Saliba, W, 2018) |
| "To compare live birth rates in women with recurrent pregnancy loss (RPL) and either autoantibodies or a coagulation abnormality, treated with low molecular weight heparin plus aspirin (LMWH/ASA) or ASA alone, and to place our results in context with other randomized clinical trials (RCT) with similar cohorts." | 5.14 | Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial. ( Barrett, J; Clark, CA; Crowther, MR; Gent, M; Ginsberg, JS; Hawker, GA; Kingdom, JC; Laskin, CA; Spitzer, KA, 2009) |
| "Aspirin combined with LMWH for APS may improve live birth rate, and detection of d-dimer levels in APS pregnant women may predict pregnancy complications and guide the use of anticoagulants." | 5.12 | Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels. ( Diao, QZ; Gu, ZD; Shi, T, 2021) |
| "To compare the efficacy of low-dose aspirin alone versus low-dose aspirin plus low molecular weight heparin in pregnant women with antiphospholipid syndrome and recurrent miscarriage as prophylaxis against pregnancy loss." | 5.10 | Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment. ( Farquharson, RG; Greaves, M; Quenby, S, 2002) |
| " Patients with a history of thromboembolism or positive findings for thrombophilia were prescribed LMWH (enoxaparin sodium, 40 mg daily) in combination with low-dose aspirin (100 mg daily) in the first trimester (group 1, n=14) or the second trimester (group 2, n=17); the remaining 15 patients received low-dose aspirin alone (group 3)." | 5.09 | Low-molecular-weight heparin for thrombophilia in pregnant women. ( Bar, J; Blickstein, D; Cohen-Sacher, B; Hod, M; Lahav, J; Merlob, P, 2000) |
| "Aspirin and heparin are widely used as preventive strategy to reduce the high risk of recurrent pregnancy loss in women with antiphospholipid antibodies (aPL)." | 5.05 | Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. ( Goddijn, M; Hamulyák, EN; Marijnen, MC; Middeldorp, S; Scheres, LJ, 2020) |
| "To determine in women with hereditary thrombophilia whether the use of the combination of low-molecular-weight heparin (LMWH) and aspirin (ASA) is better than ASA alone." | 4.93 | Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials. ( Areia, AL; Areia, M; Fonseca, E; Moura, P, 2016) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two unexplained miscarriages with or without inherited thrombophilia." | 4.90 | Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. ( de Jong, PG; Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2014) |
| "To evaluate the efficacy and safety of anticoagulant agents, such as aspirin and heparin, in women with a history of at least two miscarriages without apparent causes other than inherited thrombophilia." | 4.85 | Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. ( Di Nisio, M; Goddijn, M; Kaandorp, S; Middeldorp, S, 2009) |
| " first venous thrombosis) should be treated with warfarin to an INR 2." | 4.85 | Management of antiphospholipid syndrome. ( Khamashta, MA; Tuthill, JI, 2009) |
| " Results of the first phase III trial (PT1) that compared anagrelide/aspirin with hydroxyurea/aspirin have sparked an intense discussion, given that the combination of anagrelide and aspirin causes more bleeding complications in the gastrointestinal tract." | 4.83 | Anagrelide: what was new in 2004 and 2005? ( Petrides, PE, 2006) |
| "Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of VTE; for the prevention and treatment of systemic embolism in patients with mechanical heart valves; and, often in combination with aspirin, for the prevention of pregnancy loss in women with APLAs or thrombophilia and previous pregnancy losses." | 4.81 | Use of antithrombotic agents during pregnancy. ( Ginsberg, JS; Greer, I; Hirsh, J, 2001) |
| " Considering the clear risk of complications during pregnancy -- especially the occurrence of spontaneous abortion in the first trimester -- and the risk of intrauterine fetal death, we believe all patients should at least be treated with aspirin unless there is a contraindication." | 4.81 | Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature. ( Vanstraelen, D; Vantroyen, B, 2002) |
| "Anticoagulant therapy is indicated during pregnancy for the prevention and treatment of VTE, for the prevention and treatment of systemic embolism in patients with mechanical heart valves, and, in combination with aspirin, for the prevention of pregnancy loss in women with APLA and previous pregnancy losses." | 4.80 | Use of antithrombotic agents during pregnancy. ( Ginsberg, JS; Hirsh, J, 1998) |
| "Aspirin has a well established role in the prevention of arterial thrombosis." | 4.79 | Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997) |
| " These patients were grouped into three groups according to their treatment plan including those who received low dose aspirin (LDA) alone (group A), LDA plus LMWH after ovulation therapy (group B), and LDA plus LMWH after pregnancy confirmation (group C)." | 3.96 | D-Dimer Assay May Guide LMWH Treatment in Repeated Biochemical Pregnancy Losses in Women with Positive Antiphospholipid Antibody. ( Bao, SH; Frempong, ST; Ruan, JL, 2020) |
| "This prospective study aimed to evaluate pregnancy outcome and complications in women with recurrent pregnancy loss (RPL) and protein S (PS) deficiency, who received low dose aspirin (LDA) or LDA plus heparin (LDA/H) therapies." | 3.83 | Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss. ( Deguchi, M; Ebina, Y; Morizane, M; Shinozaki, N; Tanimura, K; Yamada, H, 2016) |
| "All the patients were treated with low dose aspirin during the pregnancy." | 3.77 | [Pregnancy and essential thrombocytemia]. ( Cambier, N; Depret, S; Deruelle, P; Ducloy, AS; Giraudet, G; Houfflin-Debarge, V; Vaast, P; Wibaut, B, 2011) |
| "To evaluate the benefit of treatment with dalteparin and low-dose aspirin (ASA) in the prevention of obstetric complications in women with inherited thrombophilia." | 3.74 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia. ( David, M; Dubois, E; Leduc, L; Rey, E; Takser, L, 2007) |
| "Live birth rates are increased by treatment with heparin and aspirin in cases of poor pregnancy outcome such as antiphospholipid syndrome." | 3.73 | Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. ( Black, S; Bose, P; Huppertz, B; Kadyrov, M; Neulen, J; Regan, L; Weissenborn, U, 2005) |
| " During pregnancy, aspirin prophylaxis was prescribed and followed by steroids after caesarian section." | 3.73 | [Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal]. ( Galicier, L; Guillevin, L; Meune, C; Salengro, E; Spaulding, C; Wahbi, K; Weber, S, 2005) |
| "Unfractionated and low-molecular-weight heparin and low-dose aspirin are used for the prevention of pregnancy loss in pregnant women with thrombophilia." | 3.72 | Effects of low-molecular-weight and unfractionated heparin on trophoblast function. ( Cartwright, JE; Mountfield, S; Quenby, S; Vince, G; Whitley, GS, 2004) |
| "Heparin prophylaxis at fixed low doses and possibly aspirin could be efficacious in preventing adverse outcomes in women carrying inherited thrombophilia with previous poor obstetric outcomes." | 3.71 | Preventing adverse obstetric outcomes in women with genetic thrombophilia. ( Brancaccio, V; Colaizzo, D; Di Minno, G; Grandone, E; Margaglione, M; Pavone, G; Sciannamé, N, 2002) |
| " If thrombophilia was diagnosed on the basis of hyperhomocysteinemia, the treatment consisted of aspirin, pyridoxine and folic acid, instead." | 3.71 | Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women. ( Aardenburg, R; de Leeuw, PW; Ekhart, TH; Peeters, LL; Spaanderman, ME; van der Heijden, OW; van Eyck, J; van Eyndhoven, HW, 2001) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "To assess the prevalence of haemostatic abnormalities in patients with an obstetric history of preeclampsia and/or fetal growth restriction and documented thrombophilia, and to evaluate the effects of low-molecular-weight heparin (LMWH) and aspirin on pregnancy outcome." | 3.70 | Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study. ( de Vries, JI; Dekker, GA; Huijgens, PC; Leeda, M; Riyazi, N; van Geijn, HP, 1998) |
| " A care of pregnancy complicated by essential thrombocythemia treated with aspirin, antiaggregating agent, throughout pregnancy and with hydroxyurea, a platelet lowering drug is reported." | 3.69 | [Essential thrombocythemia in pregnancy. A case report and general considerations]. ( Catalano, D; Dell'Isola, A; Di Rosa, G, 1997) |
| "To determine whether aspirin therapy in women at risk of pre-eclampsia alters in vitro platelet aggregation." | 3.68 | Changes in platelet reactivity following aspirin treatment for pre-eclampsia. ( Elder, MG; Sullivan, MH, 1993) |
| "A 28-year-old women with idiopathic thrombocytosis was treated with melphalan before pregnancy, which resulted in a normal platelet count." | 3.68 | Idiopathic thrombocythemia and pregnancy; a case report. ( Minkhorst, AG; Nováková, IR; van Dongen, PW, 1991) |
| " In five cases, temporary reversal of the HELLP syndrome was achieved using low-dose aspirin and corticosteroids." | 3.68 | Prolongation of premature gestation in women with hemolysis, elevated liver enzymes and low platelets. A report of five cases. ( Burke, MS; Heyborne, KD; Porreco, RP, 1990) |
| "Pregnant women with either Type B EPH gestosis or gestosis alone were treated with low dose aspirin if thrombocytopenia were present (platelet counts below 75,000) or had platelet aggregation studies if their platelet counts were above 75,000." | 3.66 | Diagnosis and treatment of pregnancy induced platelet dysfunction. ( Davis, RB; Goodlin, RC, 1983) |
| "Aspirin and heparin have been shown to have potentially beneficial effects on trophoblast implantation." | 2.79 | Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage. ( Adam, I; Ashur, BM; Elbareg, AM; Elmahashi, MO; Essadi, FM, 2014) |
| "Although low-dose aspirin is well established in PV, its indications and dosing regimens are less clear in ET." | 2.72 | Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera. ( Hobbs, G; How, J, 2021) |
| "Prednisone alone was judged to be effective in 30 patients with mild TTP-HUS (two relapses and two deaths)." | 2.67 | Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. ( Bell, WR; Braine, HG; Kickler, TS; Ness, PM, 1991) |
| " Each case showed a marked platelet decrease, from values within normal limits at the time of delivery, with no severe adverse events." | 2.58 | Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review. ( Hasegawa, M; Sakai, K; Ueda, A; Ueda, Y, 2018) |
| "Aspirin may cause teratogenicity and fetal toxicity, and perinatal mortality is increased." | 2.49 | Antithrombotic therapy for pregnant women. ( Toyoda, K, 2013) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "The optimum treatment for patients with recurrent miscarriage and a confirmed thrombophilia remains a contentious issue." | 2.48 | Recurrent miscarriage and thrombophilia: an update. ( Dawood, F; Farquharson, R; McNamee, K, 2012) |
| "Because of the rarity of primary thrombocythemia thus far only two prospectively randomized studies have been carried out to compare cyto- and thromboreductive therapies." | 2.43 | [Primary thrombocythemia: diagnosis and therapy]. ( Petrides, PE, 2006) |
| " Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis." | 2.42 | The safety of antithrombotic therapy during pregnancy. ( Ageno, W; Crotti, S; Turpie, AG, 2004) |
| "Essential thrombocythemia is a distinct clinical entity within the spectrum of myeloproliferative disorders." | 2.42 | Essential thrombocythemia. ( Green, AR; Harrison, CN, 2003) |
| "Many authors relate this factor with preeclampsia, intrauterine fetal growth retardation, spontaneous abortion, unexplained cases of still birth, placental abruption, and thromboembolic complications during and after parturition." | 2.42 | [Factor V Leiden mutation and pregnancy complications]. ( Abraitis, V; Mockeviciene, A; Mongirdiene, A, 2003) |
| "Essential thrombocythemia is a myeloproliferative disorder characterized by a persistent increase in the platelet count." | 2.40 | Essential thrombocythemia during pregnancy. ( Eliyahu, S; Shalev, E, 1997) |
| "Essential thrombocythemia is a chronic myeloproliferative disease characterized by persistent thrombocytosis and an increased risk of thromboembolic complications." | 2.40 | [A management program for primary thrombocytopenia]. ( Bruserud, O; Knutsen, H, 1999) |
| " We present simple methods for combining dose information from the study of interest with dose-response data from other epidemiologic studies or animal studies to derive plausible hypothesized effect levels." | 2.39 | Resolving discrepancies among studies: the influence of dose on effect size. ( Hertz-Picciotto, I; Neutra, RR, 1994) |
| "Aspirin (ASS) was the most frequently used drug in 47 of 93 recorded cases (51%)." | 2.39 | Essential thrombocythemia and pregnancy. ( Griesshammer, M; Heimpel, H; Pearson, TC, 1996) |
| "One pregnancy was complicated by superficial thrombophlebitis and a postpartum haemorrhage." | 2.38 | Primary thrombocythaemia in pregnancy. ( Anderson, CC; Beard, J; Hillmen, P; Lewis, SM; Pearson, TC, 1991) |
| "Antiphospholipid syndrome is associated with recurrent pregnancy loss." | 1.62 | "Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome. ( Bates, SM; Gonsalves, C; Karovitch, A; Rodger, MA; Skeith, L; Taylor, TS, 2021) |
| "Primary myelofibrosis (PMF) is a clonal myeloproliferative neoplasm that occurs most commonly in the decade six of life and it is very rare in the young persons." | 1.42 | Management of myelofibrosis during pregnancy: a case report. ( Marisavljević, D; Marković, O; Terzić, T; Tukić, L; Zivković, R, 2015) |
| "Thromboembolism is an infrequent, yet serious cause of both maternal and fetal morbidity and death during pregnancy and the puerperium." | 1.38 | Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia. ( Giannubilo, SR; Tranquilli, AL, 2012) |
| "Furthermore, the occurrence of a miscarriage in ET might be a marker for a similar event during subsequent pregnancies." | 1.35 | Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. ( Gangat, N; Schwager, S; Tefferi, A; Wolanskyj, AP, 2009) |
| "Aspirin was shown to increase oxygen affinity of hemoglobin via acetylating lysine residues and its general acetylating activity on proteins such as histones makes it also an interesting candidate to activate fetal hemoglobin." | 1.34 | Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. ( Altinoz, MA; Carin, MN; Gedikoglu, G; Ozdilli, K, 2007) |
| "Pregnancy is an initiating event for acute thrombotic thrombocytopaenic purpura (TTP)." | 1.33 | Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura. ( Cohen, H; Lee, R; Machin, S; Mackie, I; Scully, M; Starke, R, 2006) |
| "Since completion of the recurrent miscarriage analysis, 39 women conceived again." | 1.32 | Pregnancy outcome in patients with a history of recurrent spontaneous miscarriages and documented thrombophilias. ( Dekker, GA; Krabbendam, I, 2004) |
| "Essential thrombocythemia is a rare disease of unknown origin characterized by abnormal increase in the platelet count." | 1.32 | Pregnancy in essential thrombocythemia during aspirin treatment. ( Cannata, ML; Corrado, F; Ruggeri, Z; Stella, NC, 2003) |
| "Diagnosis of polycythemia vera during pregnancy is a very difficult task due to physiologic changes occurring during gestation." | 1.32 | [Polycythemia vera and pregnancy]. ( Beillat, T; Dreyfus, M; Macro, M, 2004) |
| "Deferoxamine therapy was continued throughout 2 pregnancies, while in the other it was stopped after 8 weeks: no abnormalities were noted in the children." | 1.31 | High-risk pregnancy in beta-thalassemia major women. Report of three cases. ( De Marzi, CA; Magliari, F; Perniola, R; Rosatelli, MC, 2000) |
| "Among the patients treated (n = 38) thrombophilia screening was positive in 16 patients and in the remaining 22 no causative factor was detected." | 1.31 | Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology. ( Anapliotis, A; Klearchou, N; Loufopoulos, A; Mamopoulos, A; Mamopoulos, M; Psarra, A; Tzafettas, J, 2002) |
| "Management of ET in pregnancy is still very much individualized." | 1.31 | Four pregnancies in two patients with essential thrombocythaemia--a case report. ( Devendra, K; Koh, LP; Tien, SL, 2002) |
| "Pregnancy was confirmed and therapy with platelet aggregation inhibitor was introduced." | 1.30 | Pregnancy in a patient with essential thrombocytosis. ( Appiano, G; Caremani, M; Lapini, L; Rossi, G, 1997) |
| "One pregnancy was electively terminated after extensive thrombosis in the splanchnic district requiring surgical entero-resection." | 1.29 | Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases. ( Arrigoni, L; Muggiasca, ML; Pagliaro, P; Poggio, M; Rossi, E; Russo, U, 1996) |
| "Increased risk for aplasia cutis congenita should be considered when elevated maternal and amniotic fluid alpha-fetoprotein and a distinct electrophoretic band of acetylcholinesterase are found." | 1.29 | Aplasia cutis congenita, elevated alpha-fetoprotein, and a distinct amniotic fluid acetylcholinesterase electrophoretic band. ( Cohen, RN; Dror, Y; Gelman-Kohan, Z; Hagai, Z; Juster-Reicher, A; Mogilner, B, 1994) |
| "Thrombotic thrombocytopenic purpura is a severe multisystemic disorder of unknown origin." | 1.28 | Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura. ( Eldor, A; Ezra, Y; Mordel, N; Sadovsky, E; Schenker, JG, 1989) |
| "A clinical diagnosis of systemic lupus erythematosus (SLE) was made in four women." | 1.27 | Lupus anticoagulant in pregnancy. ( Butler, WS; Liggins, GC; Lubbe, WF; Palmer, SJ, 1984) |
| " These same dosage levels also caused a severe maternal hemolytic anemia following a dramatic decrease in erythrocyte ATP levels." | 1.27 | Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits. ( Allen, HL; Bokelman, DL; Clark, RL; Cohen, SM; James, ML; Minsker, DH; Robertson, RT; Tocco, DJ, 1984) |
| "Aspirin was continuously administered throughout pregnancy to prevent thrombus formation, but no adverse effects on the delivery or the infant were observed." | 1.27 | Idiopathic thrombocythemia and pregnancy: report of a case. ( Kaibara, M; Kobayashi, T; Matsumoto, S, 1985) |
| " Potencies of estrogens varied greatly, but all compounds tested prevented DIC at adequate dosage levels." | 1.26 | Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens. ( Stamler, FW, 1977) |
| "When thrombotic thrombocytopenic purpura (TTP) occurs in pregnancy, survival of either the mother or fetus is exceedingly rare." | 1.26 | Survival following thrombotic thrombocytopenic purpura in pregnancy. ( Burkhardt, JH; Fitzgibbons, JF; Goodnight, SH; Kirk, PE, 1977) |
| "Report on 5 patients with thrombotic thrombocytopenic purpura." | 1.26 | [Thrombotic thrombocytopenic purpura: report on 5 cases and current therapy concepts]. ( Cornu, P; Gratwohl, A; Richner, J; Speck, B, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (17.86) | 18.7374 |
| 1990's | 43 (25.60) | 18.2507 |
| 2000's | 59 (35.12) | 29.6817 |
| 2010's | 29 (17.26) | 24.3611 |
| 2020's | 7 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| How, J | 1 |
| Hobbs, G | 1 |
| Bao, SH | 2 |
| Chigirin, N | 1 |
| Hoch, V | 1 |
| Ahmed, H | 1 |
| Frempong, ST | 2 |
| Zhang, M | 1 |
| Ruan, JL | 2 |
| Kwak-Kim, J | 1 |
| Karadağ, C | 1 |
| Akar, B | 1 |
| Gönenç, G | 1 |
| Aslancan, R | 1 |
| Yılmaz, N | 1 |
| Çalışkan, E | 1 |
| Hamulyák, EN | 1 |
| Scheres, LJ | 1 |
| Marijnen, MC | 1 |
| Goddijn, M | 3 |
| Middeldorp, S | 3 |
| Skeith, L | 2 |
| Rodger, MA | 1 |
| Bates, SM | 1 |
| Gonsalves, C | 1 |
| Karovitch, A | 1 |
| Taylor, TS | 1 |
| Gangat, N | 2 |
| Guglielmelli, P | 1 |
| Al-Kali, A | 1 |
| Wolanskyj-Spinner, AP | 1 |
| Camoriano, J | 1 |
| Patnaik, MM | 1 |
| Pardanani, A | 1 |
| Hanson, CA | 1 |
| Vannucchi, AM | 1 |
| Tefferi, A | 3 |
| Shi, T | 1 |
| Gu, ZD | 1 |
| Diao, QZ | 1 |
| Calhoun, B | 1 |
| Hoover, E | 1 |
| Seybold, D | 1 |
| Broce, M | 1 |
| Hill, A | 1 |
| Schaible, B | 1 |
| Bracero, LA | 1 |
| Sakai, K | 1 |
| Ueda, A | 1 |
| Hasegawa, M | 1 |
| Ueda, Y | 1 |
| Bouvier, S | 1 |
| Chea, M | 1 |
| Ripart, S | 1 |
| Hanss, M | 1 |
| de Mazancourt, P | 1 |
| Gris, JC | 1 |
| Lavi, N | 1 |
| Brenner, B | 3 |
| Avivi, I | 1 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 1 |
| Besses, C | 1 |
| Toyoda, K | 1 |
| Elmahashi, MO | 1 |
| Elbareg, AM | 1 |
| Essadi, FM | 1 |
| Ashur, BM | 1 |
| Adam, I | 1 |
| de Jong, PG | 1 |
| Kaandorp, S | 2 |
| Di Nisio, M | 2 |
| Mutlu, I | 1 |
| Mutlu, MF | 1 |
| Biri, A | 1 |
| Bulut, B | 1 |
| Erdem, M | 1 |
| Erdem, A | 1 |
| Maalej, A | 1 |
| Khallouli, A | 1 |
| Loukil, M | 1 |
| Bellassoued, O | 1 |
| Rannen, R | 1 |
| Patil, R | 1 |
| Ghosh, K | 2 |
| Damania, K | 1 |
| Bansal, V | 1 |
| Satoskar, P | 1 |
| Darekar, A | 1 |
| Shetty, S | 2 |
| Abheiden, C | 1 |
| Van Hoorn, ME | 1 |
| Hague, WM | 1 |
| Kostense, PJ | 1 |
| van Pampus, MG | 1 |
| de Vries, J | 1 |
| Zivković, R | 1 |
| Marković, O | 1 |
| Marisavljević, D | 1 |
| Terzić, T | 1 |
| Tukić, L | 1 |
| Areia, AL | 1 |
| Fonseca, E | 1 |
| Areia, M | 1 |
| Moura, P | 1 |
| Dimitrova, V | 1 |
| Dimitrov, R | 1 |
| Savov, A | 1 |
| Shinozaki, N | 1 |
| Ebina, Y | 1 |
| Deguchi, M | 1 |
| Tanimura, K | 1 |
| Morizane, M | 1 |
| Yamada, H | 1 |
| Nahas, R | 1 |
| Saliba, W | 1 |
| Elias, A | 1 |
| Elias, M | 1 |
| Roumi, JE | 1 |
| Moukhadder, HM | 1 |
| Graziadei, G | 1 |
| Pennisi, M | 1 |
| Cappellini, MD | 1 |
| Taher, AT | 1 |
| Rodger, M | 1 |
| Griesshammer, M | 3 |
| Struve, S | 1 |
| Barbui, T | 1 |
| Ruan, Y | 1 |
| Bridges, JS | 1 |
| Kumar, K | 1 |
| Raphael, JA | 1 |
| Acharjee, S | 1 |
| Welty, FK | 1 |
| Laskin, CA | 1 |
| Spitzer, KA | 1 |
| Clark, CA | 1 |
| Crowther, MR | 1 |
| Ginsberg, JS | 3 |
| Hawker, GA | 1 |
| Kingdom, JC | 1 |
| Barrett, J | 1 |
| Gent, M | 1 |
| Wolanskyj, AP | 1 |
| Schwager, S | 1 |
| Pati, S | 1 |
| Bhattacharya, S | 1 |
| Rakshit, VM | 1 |
| Espinosa, G | 1 |
| Cervera, R | 2 |
| Tuthill, JI | 1 |
| Khamashta, MA | 1 |
| Krüger, K | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 2 |
| Apter, S | 1 |
| Passamonti, F | 1 |
| Rumi, E | 1 |
| Randi, ML | 4 |
| Morra, E | 1 |
| Cazzola, M | 1 |
| Kosar, A | 1 |
| Kasapoglu, B | 1 |
| Kalyoncu, S | 1 |
| Turan, H | 1 |
| Balcik, OS | 1 |
| Gümüs, EI | 1 |
| Giraudet, G | 1 |
| Wibaut, B | 1 |
| Ducloy, AS | 1 |
| Deruelle, P | 1 |
| Depret, S | 1 |
| Cambier, N | 1 |
| Vaast, P | 1 |
| Houfflin-Debarge, V | 1 |
| Yamashita, E | 1 |
| Okada, H | 1 |
| Yorioka, H | 1 |
| Fujita, S | 1 |
| Nishi, K | 1 |
| Komiyama, Y | 1 |
| Kanzaki, H | 1 |
| Marinov, B | 2 |
| Pramatarova, T | 2 |
| Andreeva, A | 2 |
| Iarukova, N | 2 |
| Slavov, A | 2 |
| McNamee, K | 1 |
| Dawood, F | 1 |
| Farquharson, R | 1 |
| Giannubilo, SR | 1 |
| Tranquilli, AL | 1 |
| Grandone, E | 1 |
| Brancaccio, V | 1 |
| Colaizzo, D | 1 |
| Sciannamé, N | 1 |
| Pavone, G | 1 |
| Di Minno, G | 1 |
| Margaglione, M | 1 |
| Farquharson, RG | 1 |
| Quenby, S | 2 |
| Greaves, M | 1 |
| Hickstein, H | 1 |
| Barz, D | 1 |
| Külz, T | 1 |
| Korten, G | 1 |
| Müller, H | 1 |
| Schmidt, R | 1 |
| Tzafettas, J | 1 |
| Mamopoulos, A | 1 |
| Anapliotis, A | 1 |
| Loufopoulos, A | 1 |
| Psarra, A | 1 |
| Klearchou, N | 1 |
| Mamopoulos, M | 1 |
| Ruggeri, Z | 1 |
| Cannata, ML | 1 |
| Stella, NC | 1 |
| Corrado, F | 1 |
| Mertens, D | 1 |
| Alarcón-Segovia, D | 1 |
| Boffa, MC | 1 |
| Branch, W | 1 |
| Gharavi, A | 1 |
| Khamashta, M | 1 |
| Shoenfeld, Y | 1 |
| Wilson, W | 1 |
| Roubey, R | 1 |
| Lewandowski, K | 1 |
| Balcerzak, A | 1 |
| Kubiaczyk-Paluch, B | 1 |
| Breborowicz, GH | 1 |
| Abraitis, V | 1 |
| Mongirdiene, A | 1 |
| Mockeviciene, A | 1 |
| Harrison, CN | 1 |
| Green, AR | 1 |
| Krabbendam, I | 1 |
| Dekker, GA | 2 |
| Ageno, W | 1 |
| Crotti, S | 1 |
| Turpie, AG | 1 |
| Mountfield, S | 1 |
| Cartwright, JE | 1 |
| Whitley, GS | 1 |
| Vince, G | 1 |
| Wisløff, F | 1 |
| Crowther, M | 1 |
| Niittyvuopio, R | 1 |
| Juvonen, E | 1 |
| Kaaja, R | 1 |
| Oksanen, K | 1 |
| Hallman, H | 1 |
| Timonen, T | 1 |
| Ruutu, T | 1 |
| Beillat, T | 1 |
| Macro, M | 1 |
| Dreyfus, M | 1 |
| Bose, P | 1 |
| Black, S | 1 |
| Kadyrov, M | 1 |
| Weissenborn, U | 1 |
| Neulen, J | 1 |
| Regan, L | 1 |
| Huppertz, B | 1 |
| Verspyck, E | 1 |
| Marpeau, L | 1 |
| Wahbi, K | 1 |
| Salengro, E | 1 |
| Galicier, L | 1 |
| Guillevin, L | 1 |
| Spaulding, C | 1 |
| Weber, S | 1 |
| Meune, C | 1 |
| Haram, K | 1 |
| Björge, L | 1 |
| Sandset, PM | 1 |
| Petrides, PE | 2 |
| Scully, M | 1 |
| Starke, R | 1 |
| Lee, R | 1 |
| Mackie, I | 1 |
| Machin, S | 1 |
| Cohen, H | 2 |
| Yamaguchi, K | 1 |
| Hisano, M | 1 |
| Sakata, M | 1 |
| Minatogawa, Y | 1 |
| Suzuki, T | 1 |
| Ozawa, N | 1 |
| Kitagawa, M | 1 |
| Murashima, A | 1 |
| Gunther, K | 1 |
| Iwashita, T | 1 |
| Fujitani, M | 1 |
| Yamamoto, Y | 1 |
| Katsurada, T | 1 |
| Yoshida, Y | 1 |
| Altinoz, MA | 1 |
| Ozdilli, K | 1 |
| Carin, MN | 1 |
| Gedikoglu, G | 1 |
| Asghar, F | 1 |
| Zaire, M | 1 |
| Dwyer, MO | 1 |
| Bhuinneain, MN | 1 |
| Reilly, JT | 1 |
| Hossain, N | 1 |
| Paidas, MJ | 1 |
| Leduc, L | 1 |
| Dubois, E | 1 |
| Takser, L | 1 |
| Rey, E | 1 |
| David, M | 1 |
| Bick, RL | 1 |
| Dinas, K | 1 |
| Hatzipantelis, E | 1 |
| Karasmanis, K | 1 |
| Zepiridis, L | 1 |
| Mavromatidis, G | 1 |
| Bontis, J | 1 |
| Lubbe, WF | 4 |
| Butler, WS | 2 |
| Palmer, SJ | 2 |
| Liggins, GC | 3 |
| Voigt, T | 1 |
| Voigt, H | 1 |
| Boccaccio, P | 1 |
| Ghio, R | 1 |
| Ratti, M | 1 |
| Casciaro, S | 1 |
| Rattenni, S | 1 |
| Sergnese, G | 1 |
| Walker, EB | 1 |
| Clark, RL | 1 |
| Robertson, RT | 1 |
| Minsker, DH | 1 |
| Cohen, SM | 1 |
| Tocco, DJ | 1 |
| Allen, HL | 1 |
| James, ML | 1 |
| Bokelman, DL | 1 |
| Vandekerckhove, F | 1 |
| Noens, L | 1 |
| Colardyn, F | 1 |
| Thiery, M | 1 |
| Delbarge, W | 1 |
| Goodlin, RC | 1 |
| Davis, RB | 1 |
| Makatsariia, AD | 1 |
| Limonova, SG | 1 |
| Richner, J | 1 |
| Gratwohl, A | 1 |
| Cornu, P | 1 |
| Speck, B | 1 |
| Jespersen, J | 1 |
| Ron-el, R | 1 |
| Vinder, A | 1 |
| Golan, A | 1 |
| Herman, A | 1 |
| Raziel, A | 1 |
| Caspi, E | 1 |
| Sidi, Y | 1 |
| Dror, Y | 1 |
| Gelman-Kohan, Z | 1 |
| Hagai, Z | 1 |
| Juster-Reicher, A | 1 |
| Cohen, RN | 1 |
| Mogilner, B | 1 |
| Zahner, J | 1 |
| Wehmeier, A | 1 |
| Schneider, W | 1 |
| Edelman, P | 1 |
| Rouquette, AM | 1 |
| Yamamoto, R | 1 |
| Hirahatake, K | 1 |
| Yamaguchi, M | 1 |
| Sato, C | 1 |
| Fernandez, H | 2 |
| Hertz-Picciotto, I | 1 |
| Neutra, RR | 1 |
| Pardini, S | 1 |
| Dore, F | 1 |
| Murineddu, M | 1 |
| Bontigli, S | 1 |
| Longinotti, M | 1 |
| Grigliotti, B | 1 |
| Spano, B | 1 |
| Sullivan, MH | 2 |
| Elder, MG | 2 |
| Olson, NA | 1 |
| Ezra, Y | 2 |
| Rose, M | 1 |
| Eldor, A | 2 |
| Delage, R | 1 |
| Demers, C | 1 |
| Cantin, G | 1 |
| Roy, J | 1 |
| Pagliaro, P | 1 |
| Arrigoni, L | 1 |
| Muggiasca, ML | 1 |
| Poggio, M | 1 |
| Russo, U | 1 |
| Rossi, E | 1 |
| Heimpel, H | 2 |
| Pearson, TC | 3 |
| Alqadah, F | 1 |
| Eliyahu, S | 1 |
| Shalev, E | 1 |
| Dell'Isola, A | 1 |
| Di Rosa, G | 1 |
| Catalano, D | 1 |
| Bangerter, M | 1 |
| van Vliet, HH | 1 |
| Michiels, JJ | 1 |
| Willoughby, SJ | 1 |
| Fairhead, S | 1 |
| Woodcock, BE | 1 |
| Rossi, G | 1 |
| Appiano, G | 1 |
| Lapini, L | 1 |
| Caremani, M | 1 |
| Cyrkowicz, A | 1 |
| Przybycień, J | 1 |
| Riyazi, N | 1 |
| Leeda, M | 1 |
| de Vries, JI | 1 |
| Huijgens, PC | 1 |
| van Geijn, HP | 1 |
| Nelson-Piercy, C | 1 |
| Hirsh, J | 2 |
| Kaaja, RJ | 1 |
| Leinonen, PJ | 1 |
| Luzzatto, G | 1 |
| Fabris, F | 3 |
| Knutsen, H | 1 |
| Bruserud, O | 1 |
| Rossi, C | 2 |
| Girolami, A | 2 |
| Perniola, R | 1 |
| Magliari, F | 1 |
| Rosatelli, MC | 1 |
| De Marzi, CA | 1 |
| Younis, JS | 2 |
| Ohel, G | 1 |
| Haddad, S | 1 |
| Lanir, N | 1 |
| Ben-Ami, M | 1 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Bar, J | 1 |
| Cohen-Sacher, B | 1 |
| Hod, M | 1 |
| Blickstein, D | 1 |
| Lahav, J | 1 |
| Merlob, P | 1 |
| Macchi, L | 1 |
| Sarfati, R | 1 |
| Guicheteau, M | 1 |
| Chamlian, V | 1 |
| Pourrat, O | 1 |
| Gruel, Y | 1 |
| Magnin, G | 1 |
| Brizard, A | 1 |
| Boinot, C | 1 |
| Greer, I | 1 |
| Spaanderman, ME | 1 |
| Aardenburg, R | 1 |
| Ekhart, TH | 1 |
| van Eyndhoven, HW | 1 |
| van der Heijden, OW | 1 |
| van Eyck, J | 1 |
| de Leeuw, PW | 1 |
| Peeters, LL | 1 |
| Briere, J | 1 |
| Guilmin, F | 1 |
| Wright, CA | 1 |
| Fayyad, AM | 1 |
| Brummitt, DR | 1 |
| Barker, HF | 1 |
| Spooner, SF | 1 |
| Soriano, D | 1 |
| Carp, H | 1 |
| Seidman, DS | 1 |
| Schiff, E | 1 |
| Langevitz, P | 1 |
| Mashiach, S | 1 |
| Proia, A | 1 |
| Paesano, R | 1 |
| Torcia, F | 1 |
| Annino, L | 1 |
| Capria, S | 1 |
| Ferrari, A | 1 |
| Ferrazza, G | 1 |
| Pacifici, E | 1 |
| Pantalissi, A | 1 |
| Meloni, G | 1 |
| Vantroyen, B | 1 |
| Vanstraelen, D | 1 |
| Woo, YL | 1 |
| Allard, S | 1 |
| Letsky, E | 1 |
| de Swiet, M | 1 |
| Koh, LP | 1 |
| Devendra, K | 1 |
| Tien, SL | 1 |
| Stamler, FW | 1 |
| Everett, RB | 2 |
| Worley, RJ | 2 |
| MacDonald, PC | 2 |
| Chand, S | 1 |
| Gant, NF | 2 |
| Tamura, T | 1 |
| Fitzgibbons, JF | 1 |
| Goodnight, SH | 1 |
| Burkhardt, JH | 1 |
| Kirk, PE | 1 |
| Kakkar, VV | 1 |
| Ben Ismail, M | 1 |
| Ghariani, M | 1 |
| Jais, JM | 1 |
| Chow, EY | 1 |
| Haley, LP | 1 |
| Vickars, LM | 1 |
| Solal-Céligny, P | 1 |
| Tertian, G | 1 |
| Fusi, L | 1 |
| Brosens, J | 1 |
| Rozdzinski, E | 1 |
| Hertenstein, B | 1 |
| Schmeiser, T | 1 |
| Seifried, E | 1 |
| Kurrle, E | 1 |
| Mallett, SV | 1 |
| Platt, M | 1 |
| Breart, G | 1 |
| Beaufils, M | 1 |
| Uzan, S | 1 |
| Orlikowski, CE | 1 |
| Moodley, J | 1 |
| Rocke, DA | 1 |
| Minkhorst, AG | 1 |
| Nováková, IR | 1 |
| van Dongen, PW | 1 |
| Pineo, GF | 1 |
| Blahey, WB | 1 |
| Beard, J | 1 |
| Hillmen, P | 1 |
| Anderson, CC | 1 |
| Lewis, SM | 1 |
| Bell, WR | 1 |
| Braine, HG | 1 |
| Ness, PM | 1 |
| Kickler, TS | 1 |
| Heyborne, KD | 1 |
| Burke, MS | 1 |
| Porreco, RP | 1 |
| Wehrmacher, WH | 1 |
| Messmore, HL | 1 |
| Mordel, N | 1 |
| Sadovsky, E | 1 |
| Schenker, JG | 1 |
| Gancel, A | 1 |
| Courtois, H | 1 |
| Doucet, J | 1 |
| Schrub, JC | 1 |
| Rick, ME | 1 |
| Williams, SB | 1 |
| Sacher, RA | 1 |
| McKeown, LP | 1 |
| Rigby, PG | 1 |
| Isada, N | 1 |
| Kessler, C | 1 |
| Larsen, J | 1 |
| Weingold, A | 1 |
| Falconer, J | 1 |
| Pineo, G | 1 |
| Blahey, W | 1 |
| Bowen, T | 1 |
| Docksteader, B | 1 |
| Jadusingh, I | 1 |
| Kaibara, M | 1 |
| Kobayashi, T | 1 |
| Matsumoto, S | 1 |
| Ambrose, A | 1 |
| Welham, RT | 1 |
| Cefalo, RC | 1 |
| Mehta, BC | 1 |
| Jhaveri, K | 1 |
| Patel, JC | 1 |
| Huntsman, RG | 1 |
| Lehmann, H | 1 |
| Dacie, JV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome[NCT02303171] | Phase 4 | 100 participants (Anticipated) | Interventional | 2014-11-30 | Recruiting | ||
| Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS[NCT00180778] | Phase 1/Phase 2 | 90 participants (Anticipated) | Interventional | 2005-10-31 | Not yet recruiting | ||
| Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial[NCT01051778] | Phase 2 | 60 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| A Randomized Controlled Trial Comparing Low Molecular Weight Heparin and Aspirin to Aspirin Alone in Women With Unexplained Recurrent Pregnancy Loss[NCT00564174] | 88 participants (Actual) | Interventional | 2000-03-31 | Terminated (stopped due to interim analysis found no difference in LB rate and lower than expected event rate) | |||
| A Pilot Study Assessing the Feasibility of a Randomized Controlled Trial Evaluating Aspirin Versus Low-molecular-weight Heparin (LMWH) and Aspirin in Women With Antiphospholipid Syndrome and Pregnancy Loss[NCT03100123] | Early Phase 1 | 1 participants (Actual) | Interventional | 2017-11-06 | Terminated (stopped due to Pilot deemed not feasible by Steering Committee due to recruitment rate.) | ||
| Role of LMWH (Enoxaparine) With or Without Aspirin in the Prevention of Habitual Abortion; Special Attention to the Thrombophilic Status of the Mother[NCT00959621] | Phase 3 | 220 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| The Effects of Aspirin in Gestation and Reproduction: A Multi-center, Controlled, Double-blind Randomized Trial.[NCT00467363] | 1,228 participants (Actual) | Interventional | 2007-06-30 | Completed | |||
| Pregnancy Outcomes in Women With Unexplained Recurrent Pregnancy Loss Treated With Low Dose Aspirin and Unfractionated Heparin[NCT02144064] | Phase 3 | 200 participants (Anticipated) | Interventional | 2019-06-23 | Recruiting | ||
| A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS)[NCT01661439] | 316 participants (Anticipated) | Observational | 2012-03-31 | Recruiting | |||
| Low Dose Aspirin and Low-molecular-weight Heparin in the Treatment of Pregnant Libyan Women With Recurrent Miscarriage[NCT01917799] | Phase 4 | 150 participants (Anticipated) | Interventional | 2009-01-31 | Recruiting | ||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| Induction of Labor at Term Versus Expectant Management Among Women With Abnormal Maternal Serum Biochemical Markers: A Randomized Controlled Trial[NCT02754635] | 320 participants (Anticipated) | Interventional | 2016-03-31 | Recruiting | |||
| Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy)[NCT03152058] | Phase 2 | 55 participants (Anticipated) | Interventional | 2017-05-17 | Recruiting | ||
| A Retrospective, Observational Study on the Response to Caplacizumab Treatment in aTTP Patients: the Italian Experience (ROSCAPLI)[NCT05262881] | 50 participants (Anticipated) | Observational | 2022-03-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Live birth occurs when a fetus (> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord. (NCT01051778)
Timeframe: pregnancy > 24weeks gestation
| Intervention | Percentage of pregnancies (Number) |
|---|---|
| Enoxaparin 40 mg /Day Plus Low Dose Aspirin | 24 |
| Heparin Calcium 5,000 U Twice Daily Plus Low Dose Aspirin | 20 |
Proportion of eligible subjects who provide consent. (NCT03100123)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Consented Eligible Patients | 1 |
Crossover rate between standard of care and experimental study arms. (NCT03100123)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Crossover Rate | 0 |
Proportion of screened patients who meet eligibility criteria (i.e. patients who meet inclusion criteria and are also eligible based on exclusion criteria). (NCT03100123)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Screened Patients Who Met Eligibility Criteria | 4 |
Proportion of sites requiring >18 months to obtain all required approvals/contracts from time of delivery of all study documents. (NCT03100123)
Timeframe: 18 months
| Intervention | Sites (Number) |
|---|---|
| Approval Timeline | 1 |
Level of compliance with study drug through patient recall and patient medication diary. (NCT03100123)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Standard of Care Arm | 0 |
| Experimental Arm | 1 |
The primary feasibility outcome of the pilot trial is the mean recruitment rate per center per month. (NCT03100123)
Timeframe: 24 months
| Intervention | participants (Number) |
|---|---|
| Experimental Arm | 1 |
Proportion of withdrawals/loss to follow-up among randomized patients. (NCT03100123)
Timeframe: 24 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Withdrawal/Lost to Follow-up | 0 |
Partial or complete abruption (ie, premature separation of the placenta) (NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 7 |
| Placebo | 5 |
(NCT00467363)
Timeframe: 8-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 374 |
| Placebo | 346 |
Implantation failures (NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 28 |
| Placebo | 27 |
(NCT00467363)
Timeframe: within 6 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 3 |
| Placebo | 3 |
(NCT00467363)
Timeframe: until 40 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 4 |
| Placebo | 6 |
(NCT00467363)
Timeframe: within 8-weeks of gestation
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 394 |
| Placebo | 363 |
Live birth was obtained prospectively by maternal report and abstraction from medical records by trained staff . (NCT00467363)
Timeframe: after delivery
| Intervention | livebirths (Number) |
|---|---|
| Aspirin | 309 |
| Placebo | 286 |
(NCT00467363)
Timeframe: 8 weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 0 |
| Placebo | 0 |
(NCT00467363)
Timeframe: until delivery
| Intervention | participants (Number) |
|---|---|
| Aspirin | 32 |
| Placebo | 30 |
Includes preembryonic and embryonic losses (exclusive of implantation failures) (NCT00467363)
Timeframe: less than 10-weeks
| Intervention | pregnancy (Number) |
|---|---|
| Aspirin | 56 |
| Placebo | 53 |
(NCT00467363)
Timeframe: until delivery
| Intervention | infants (Number) |
|---|---|
| Aspirin | 22 |
| Placebo | 31 |
birthweight (NCT00467363)
Timeframe: until delivery
| Intervention | grams (Mean) |
|---|---|
| Aspirin | 3327 |
| Placebo | 3315 |
(NCT00467363)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Aspirin | 2 |
| Placebo | 2 |
50 reviews available for aspirin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Management Issues and Controversies in Low-Risk Patients with Essential Thrombocythemia and Polycythemia Vera.
Topics: Animals; Aspirin; Disease Management; Female; Humans; Phlebotomy; Platelet Aggregation Inhibitors; P | 2021 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.
Topics: Abortion, Habitual; Antibodies, Anticardiolipin; Antibodies, Antiphospholipid; Anticoagulants; Aspir | 2020 |
Meta-analysis on aspirin combined with low-molecular-weight heparin for improving the live birth rate in patients with antiphospholipid syndrome and its correlation with d-dimer levels.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2021 |
Efficacy and safety of interferon alpha for essential thrombocythemia during pregnancy: two cases and a literature review.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Interferon-alpha; Platelet Count; Pregnan | 2018 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Antithrombotic therapy for pregnant women.
Topics: Aspirin; Contraindications; Cooperative Behavior; Dose-Response Relationship, Drug; Drug Labeling; F | 2013 |
Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Enoxaparin; Female; Heparin, | 2014 |
Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Birth Weight; Female; Gestational Age; Heparin, Low-Mol | 2016 |
Anticoagulants to prevent recurrent placenta-mediated pregnancy complications: Is it time to put the needles away?
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Placent | 2017 |
Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.
Topics: Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibitors; Polycythemi | 2008 |
Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecul | 2009 |
Thromboprophylaxis and obstetric management of the antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Catastrophic Illness; Drug Therapy, Combi | 2009 |
Anti-phospholipid antibodies and other immunological causes of recurrent foetal loss--a review of literature of various therapeutic protocols.
Topics: Abortion, Spontaneous; Anti-Inflammatory Agents; Antibodies, Antiphospholipid; Aspirin; Clinical Tri | 2009 |
Management of antiphospholipid syndrome.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Fibrinolyt | 2009 |
Recurrent miscarriage and thrombophilia: an update.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Evidence-Based Medicine; Fem | 2012 |
Antibody-mediated thrombosis and pregnancy loss.
Topics: Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination | 2003 |
Prophylaxis of the antiphospholipid syndrome: a consensus report.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Female; Humans; Lupus Erythematosus, Systemic; P | 2003 |
[Factor V Leiden mutation and pregnancy complications].
Topics: Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; Aspirin; Factor V; Fem | 2003 |
Essential thrombocythemia.
Topics: Aspirin; Diagnosis, Differential; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; R | 2003 |
The safety of antithrombotic therapy during pregnancy.
Topics: Anticoagulants; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Practic | 2004 |
Evidence-based treatment of the antiphospholipid syndrome: I. Pregnancy failure.
Topics: Abortion, Habitual; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Clinical Trials as Topic; Ev | 2004 |
Pregnancy in essential thrombocythaemia: experience with 40 pregnancies.
Topics: Abortion, Spontaneous; Anticoagulants; Aspirin; Eclampsia; Female; Fetal Death; Finland; Humans; Pla | 2004 |
[Thrombophilias and vascular placental pathology. A survey of the literature].
Topics: Activated Protein C Resistance; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cohort Studies; | 2005 |
Anagrelide: what was new in 2004 and 2005?
Topics: Antineoplastic Agents; Aspirin; Blood Platelets; Clinical Trials, Phase III as Topic; Drug Therapy, | 2006 |
[Primary thrombocythemia: diagnosis and therapy].
Topics: Adult; Aged; Aspirin; Child; Diagnosis, Differential; Drug Therapy, Combination; Enzyme Inhibitors; | 2006 |
Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.
Topics: Anticoagulants; Aspirin; Female; Fetal Death; Fetal Growth Retardation; Heparin; Humans; Immunoglobu | 2007 |
Antiphospholipid syndrome in pregnancy.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin | 2008 |
[Disseminated intravascular coagulation. II. Therapeutic problems].
Topics: Antifibrinolytic Agents; Antithrombin III Deficiency; Anuria; Aprotinin; Aspirin; Blood Transfusion; | 1982 |
[Anticoagulants and pregnancy].
Topics: Anticoagulants; Aspirin; Blood Platelets; Coumarins; Disseminated Intravascular Coagulation; Female; | 1981 |
[Pregnancy in essential thrombocythemia. Manifestation time and risk for mother and child].
Topics: Abortion, Spontaneous; Adult; Aspirin; Female; Fetal Death; Growth Disorders; Humans; Infant, Newbor | 1995 |
Evaluation of the obstetrical risks of the antiphospholipid syndrome and therapeutic management.
Topics: Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Glucocorticoids; Heparin; | 1995 |
Resolving discrepancies among studies: the influence of dose on effect size.
Topics: Aspirin; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Ethylene Oxide; Female; | 1994 |
Therapy and prevention of thrombotic thrombocytopenic purpura during pregnancy: a clinical study of 16 pregnancies.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Combined Modality Therapy; Diagnostic Errors; Dipyridamole; | 1996 |
Treatment of essential thrombocythemia during pregnancy with interferon-alpha.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Interferon-alpha; Male; Platelet Aggregation Inhibi | 1996 |
Essential thrombocythemia and pregnancy.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Aspirin; Busulfan; Combined Modality Therapy; Di | 1996 |
Essential thrombocythemia during pregnancy.
Topics: Adult; Anticoagulants; Aspirin; Dipyridamole; Female; Heparin; Humans; Platelet Aggregation Inhibito | 1997 |
Aspirin in essential thrombocythemia: status quo and quo vadis.
Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome | 1997 |
[Intra-uterine fetal death syndrome--not only a gynecologic problem].
Topics: Adrenocorticotropic Hormone; Aspirin; Blood Coagulation Disorders; Female; Fetal Death; Heparin; Hum | 1997 |
Prevention of thromboembolism in pregnancy.
Topics: Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Aggregation Inhibit | 1998 |
Use of antithrombotic agents during pregnancy.
Topics: Administration, Oral; Antibodies, Antiphospholipid; Aspirin; Female; Fetus; Fibrinolytic Agents; Hea | 1998 |
[A management program for primary thrombocytopenia].
Topics: Adult; Aged; Anticoagulants; Aspirin; Female; Guidelines as Topic; Humans; Hydroxyurea; Interferon T | 1999 |
Use of antithrombotic agents during pregnancy.
Topics: Aspirin; Female; Fetus; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregn | 2001 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
A single institutional experience with 43 pregnancies in essential thrombocythemia.
Topics: Abortion, Induced; Abortion, Spontaneous; Abruptio Placentae; Adult; Anticoagulants; Aspirin; Busulf | 2001 |
Thrombotic thrombocytopenic purpura and pregnancy: a case report and a review of the literature.
Topics: Adult; Aspirin; Disease Management; Female; Heparin; Humans; Practice Guidelines as Topic; Pregnancy | 2002 |
Management of essential thrombocythemia during pregnancy with aspirin, interferon alpha-2a and no treatment. A comparative analysis of the literature.
Topics: Abortion, Spontaneous; Aspirin; Blood Component Removal; Female; Fetal Death; Gestational Age; Human | 2002 |
Vascular reactivity to angiotensin II in human pregnancy.
Topics: Adolescent; Angiotensin II; Animals; Aspirin; Blood Pressure; Blood Volume; Dogs; Female; Haplorhini | 1978 |
[Pregnancy in patients with essential thrombocythemia. Three cases].
Topics: Adult; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Platelet Count; Postpartum Period; Pr | 1992 |
Primary thrombocythaemia in pregnancy.
Topics: Abortion, Incomplete; Adult; Aspirin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologi | 1991 |
Lupus anticoagulant and pregnancy.
Topics: Aspirin; Autoantibodies; Blood Coagulation Factors; Female; Fetal Death; Fetal Diseases; Fetal Growt | 1985 |
9 trials available for aspirin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Aspirin, low molecular weight heparin, or both in preventing pregnancy complications in women with recurrent pregnancy loss and factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Administration Schedule; Drug Therapy, Comb | 2020 |
Low dose aspirin and low-molecular-weight heparin in the treatment of pregnant Libyan women with recurrent miscarriage.
Topics: Abortion, Habitual; Adult; Aspirin; Birth Weight; Embryo Implantation; Enoxaparin; Female; Fibrinoly | 2014 |
Does low-molecular-weight heparin influence fetal growth or uterine and umbilical arterial Doppler in women with a history of early-onset uteroplacental insufficiency and an inheritable thrombophilia? Secondary randomised controlled trial results.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Blood Flow Velocity; Drug Therapy, Combination; Female | 2016 |
The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages.
Topics: Abortion, Habitual; Adolescent; Adult; Anticoagulants; Aspirin; Enoxaparin; Female; Humans; Middle A | 2018 |
Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial.
Topics: Abortion, Habitual; Adult; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndrome; Aspir | 2009 |
Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment.
Topics: Abortion, Spontaneous; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Confidence | 2002 |
Low-molecular-weight heparin for thrombophilia in pregnant women.
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weigh | 2000 |
Management and outcome of pregnancy in women with thrombophylic disorders and past cerebrovascular events.
Topics: Adult; Anticoagulants; Aspirin; Birth Weight; Cerebrovascular Disorders; Cohort Studies; Female; Fib | 2002 |
Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.
Topics: Adolescent; Adult; Aged; Aspirin; Blood Transfusion; Dipyridamole; Female; Hemolytic-Uremic Syndrome | 1991 |
109 other studies available for aspirin and Complications, Hematologic Pregnancy
| Article | Year |
|---|---|
Uterine Radial Artery Resistance Index Predicts Reproductive Outcome in Women with Recurrent Pregnancy Losses and Thrombophilia.
Topics: Abortion, Habitual; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Live Bir | 2019 |
D-Dimer Assay May Guide LMWH Treatment in Repeated Biochemical Pregnancy Losses in Women with Positive Antiphospholipid Antibody.
Topics: Abortion, Habitual; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Female; Fibrin | 2020 |
"Part of the Ritual": Exploring Patient and Physician Decision Making Regarding Anticoagulation Use in Obstetric Antiphospholipid Syndrome.
Topics: Abortion, Spontaneous; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Attitude of Health Person | 2021 |
Pregnancy in patients with myelofibrosis: Mayo-Florence series of 24 pregnancies in 16 women.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Diabetes, Gestational; Female; Fetal Death; Hemo | 2021 |
Outcomes in an obstetrical population with hereditary thrombophilia and high tobacco use.
Topics: Adult; Anticoagulants; Aspirin; Case-Control Studies; Comorbidity; Female; Fetal Growth Retardation; | 2018 |
Successful Pregnancy under Fibrinogen Substitution with Heparin and Aspirin in a Woman with Dysfibrinogenemia Revealed by Placental Abruption.
Topics: Abruptio Placentae; Afibrinogenemia; Aspirin; Cesarean Section; Consanguinity; Female; Fibrinogen; G | 2018 |
Management of pregnant women with myeloproliferative neoplasms.
Topics: Adult; Aspirin; Blood Viscosity; Female; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Inc | 2013 |
Effects of anticoagulant therapy on pregnancy outcomes in patients with thrombophilia and previous poor obstetric history.
Topics: Abortion, Habitual; Anticoagulants; Apgar Score; Aspirin; Birth Weight; Blood Coagulation Factors; D | 2015 |
[Post-contusive subfoveolar hematoma in a pregnant women taking aspegic].
Topics: Adult; Aspirin; Contusions; Eye Injuries; Female; Fovea Centralis; Hematoma; Humans; Lysine; Papille | 2015 |
Effect of anticoagulant therapy on cell-derived microparticles and pregnancy outcome in women with pregnancy loss.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Case-Control Studies; Cell-Derived Microparticle | 2015 |
Management of myelofibrosis during pregnancy: a case report.
Topics: Adult; Aspirin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fibrinolytic | 2015 |
[INDICATIONS FOR ANTITHROMBOTIC MEDICATION DURING PREGNANCY--ANALYSIS OF CURRENT PRACTICES IN BULGARIA].
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Bulgaria; Female; Heparin; Heparin, Low-Molecula | 2015 |
Protein S deficiency complicated pregnancy in women with recurrent pregnancy loss.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Birth Weight; Comorbidity; Drug Th | 2016 |
Pregnancy in β-thalassemia intermedia at two tertiary care centers in Lebanon and Italy: A follow-up report on fetal and maternal outcomes.
Topics: Abortion, Habitual; Abortion, Spontaneous; Aspirin; beta-Thalassemia; Birth Weight; Cesarean Section | 2017 |
Complete resolution of a mitral valve vegetation with anticoagulation in seronegative antiphospholipid syndrome.
Topics: Abortion, Habitual; Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Cesarean Section; Fem | 2008 |
Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.
Topics: Abortion, Spontaneous; Adolescent; Adult; Aspirin; Female; Humans; Janus Kinase 2; Leukocyte Count; | 2009 |
Pregnancy complicated by Budd-Chiari syndrome and antiphospholipid syndrome.
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Budd-Chiari Syndrome; Cesarean Section; Drug The | 2009 |
[Recurrent spontaneous abortion--is heparin expendable to recurrence prophylaxis?].
Topics: Abortion, Habitual; Adult; Antibodies, Antinuclear; Anticoagulants; Antiphospholipid Syndrome; Aspir | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies.
Topics: Aspirin; Female; Genotype; Humans; Janus Kinase 2; Mutation; Phenotype; Platelet Aggregation Inhibit | 2010 |
Treatment of adverse perinatal outcome in inherited thrombophilias: a clinical study.
Topics: Adult; Anticoagulants; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy | 2011 |
[Pregnancy and essential thrombocytemia].
Topics: Adult; Aspirin; Female; Hospitals, University; Humans; Platelet Aggregation Inhibitors; Pregnancy; P | 2011 |
Successful management of pregnancy-associated thrombotic thrombocytopenic purpura by monitoring ADAMTS13 activity.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers | 2012 |
[Our experience with management of inherited thrombophilia during pregnancy. Preliminary report].
Topics: Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pregnancy Co | 2011 |
[Our experience with management of inherited thrombophilia during pregnancy: preliminary report].
Topics: Aspirin; Factor V; Female; Fibrinolytic Agents; Genetic Testing; Heparin, Low-Molecular-Weight; Huma | 2011 |
Anticoagulant therapy during pregnancy for maternal and fetal acquired and inherited thrombophilia.
Topics: Anticoagulants; Aspirin; Bone Density; Breast Feeding; Chondroitin Sulfates; Dermatan Sulfate; Femal | 2012 |
Preventing adverse obstetric outcomes in women with genetic thrombophilia.
Topics: Aspirin; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Humans; Pregnancy; Pregnancy Complication | 2002 |
Protein A immunoadsorption in a pregnant woman with habitual abortion.
Topics: Abortion, Habitual; Abortion, Spontaneous; Activated Protein C Resistance; Adult; Anticoagulants; An | 2002 |
Thromboprophylaxis throughout pregnancy in women with previous history of recurrent miscarriages of unknown aetiology.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Cohort Studies; Drug Administration Schedule; Fe | 2002 |
Pregnancy in essential thrombocythemia during aspirin treatment.
Topics: Adult; Aspirin; Cesarean Section; Drug Administration Schedule; Female; Humans; Infant, Newborn; Mal | 2003 |
[Successful pregnancy outcome in the woman with thrombophilia and multiple miscarriages].
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Cesarean Section; Factor V; Female; Heterozygote | 2003 |
Pregnancy outcome in patients with a history of recurrent spontaneous miscarriages and documented thrombophilias.
Topics: Abortion, Habitual; Adult; Antibodies, Antiphospholipid; Aspirin; Female; Folic Acid; Heparin, Low-M | 2004 |
Effects of low-molecular-weight and unfractionated heparin on trophoblast function.
Topics: Anticoagulants; Aspirin; Cell Line; Cell Movement; Dose-Response Relationship, Drug; Female; Heparin | 2004 |
[Polycythemia vera and pregnancy].
Topics: Adult; Antisickling Agents; Aspirin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hum | 2004 |
Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure.
Topics: Abortion, Habitual; Anticoagulants; Apoptosis; Aspirin; Cell Line; Dose-Response Relationship, Drug; | 2005 |
[Acute myocardial infarction complicating primary antiphospholipid syndrome after aspirin and steroids withdrawal].
Topics: Adrenal Cortex Hormones; Adult; Angioplasty, Balloon, Coronary; Antiphospholipid Syndrome; Aspirin; | 2005 |
Successful preconceptional prophylactic treatment with combined acetyl salicylic acid and low-molecular heparin (Fragmin) in a case of antiphospholipid-antibody syndrome with prior life-threatening hemolysis, elevated liver enzymes and low-platelet syndro
Topics: Anticoagulants; Antiphospholipid Syndrome; Aspirin; Drug Therapy, Combination; Female; HELLP Syndrom | 2005 |
Successful management of pregnancy in women with a history of thrombotic thrombocytopaenic purpura.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Deriv | 2006 |
Periodic plateletpheresis during pregnancy in a high-risk patient with essential thrombocythemia.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Aspirin; Blood Flow Velocity; Cesarean Section; Female | 2006 |
Successful pregnancy despite thrombotic thrombocytopenic purpura in the first trimester.
Topics: Anti-Inflammatory Agents; Aspirin; Blood Component Transfusion; Dexamethasone; Female; Humans; Live | 2006 |
Interferon-alfa treatment of essential thrombocythemia during pregnancy.
Topics: Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Female; Fetal Diseases; Humans; Immunolog | 2006 |
Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale.
Topics: Aspirin; Blood Transfusion, Intrauterine; Dose-Response Relationship, Drug; Drug Therapy, Combinatio | 2007 |
Management of thrombophiliac problems during pregnancy.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Female; Heparin, Low-Molecular-Weight; Humans; Pregnancy; | 2007 |
Practical approach to treating essential thrombocythaemia: case studies.
Topics: Adult; Aspirin; Disease Management; Female; Humans; Hydroxyurea; Interferon-alpha; Leg Ulcer; Male; | 2007 |
Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia.
Topics: Abruptio Placentae; Adult; Anticoagulants; Aspirin; Dalteparin; Drug Therapy, Combination; Female; F | 2007 |
Improving the outcome of pregnancy in essential thrombocythaemia: The role of aspirin.
Topics: Adult; Aspirin; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, | 2008 |
Fetal survival after prednisone suppression of maternal lupus-anticoagulant.
Topics: Adult; Antibodies, Antinuclear; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Fem | 1983 |
[Prophylaxis of thrombosis in surgical gynecology and obstetrics (author's transl)].
Topics: Adult; Aged; Aspirin; Bandages; Dextrans; Dose-Response Relationship, Drug; Early Ambulation; Female | 1980 |
Chorea gravidarum associated with circulating lupus anticoagulant: successful outcome of pregnancy with prednisone and aspirin therapy. Case report.
Topics: Adult; Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Chorea; Female; Humans; Infa | 1983 |
Lupus anticoagulant in pregnancy.
Topics: Aspirin; Blood Coagulation Disorders; Blood Coagulation Factors; Chorea; Drug Therapy, Combination; | 1984 |
Diflunisal-induced maternal anemia as a cause of teratogenicity in rabbits.
Topics: Abnormalities, Drug-Induced; Adenosine Triphosphate; Anemia, Hemolytic; Animals; Antioxidants; Aspir | 1984 |
Thrombotic thrombocytopenic purpura mimicking toxemia of pregnancy.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Diagnosis, Differential; Dipyridamole; Female; Fetal Death; | 1984 |
Diagnosis and treatment of pregnancy induced platelet dysfunction.
Topics: Adult; Aspirin; Dexamethasone; Female; Humans; Plasma Substitutes; Platelet Aggregation; Pre-Eclamps | 1983 |
[Thrombotic thrombocytopenic purpura: report on 5 cases and current therapy concepts].
Topics: Adult; Aspirin; Dipyridamole; Evaluation Studies as Topic; Exchange Transfusion, Whole Blood; Female | 1981 |
Disseminated intravascular coagulation in toxaemia of pregnancy. Correction of the decreased platelet counts and raised levels of serum uric acid and fibrin(ogen) degradation products by aspirin.
Topics: Adult; Aspirin; Disseminated Intravascular Coagulation; Female; Fibrin Fibrinogen Degradation Produc | 1980 |
The use of intravenous gammaglobulin, heparin and aspirin in the maintenance of pregnancy of freeze thawed embryo in a patient with lupus-type anticoagulant.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Cryopreservation; Drug Therapy, Combination; Embryo Trans | 1993 |
Aplasia cutis congenita, elevated alpha-fetoprotein, and a distinct amniotic fluid acetylcholinesterase electrophoretic band.
Topics: Acetylcholinesterase; Adult; alpha-Fetoproteins; Amniotic Fluid; Aspirin; Diseases in Twins; Ectoder | 1994 |
[A case of pregnancy with essential thrombocythemia].
Topics: Adult; Aspirin; Dipyridamole; Female; Heparin; Humans; Pregnancy; Pregnancy Complications, Hematolog | 1995 |
[Essential thrombocythemia and pregnancy].
Topics: Aspirin; Female; Humans; Hydroxyurea; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Out | 1994 |
Alpha 2b-interferon therapy and pregnancy--report of a case of essential thrombocythemia.
Topics: Adult; Aspirin; Female; Humans; Infant, Newborn; Infarction; Interferon alpha-2; Interferon-alpha; P | 1993 |
Changes in platelet reactivity following aspirin treatment for pre-eclampsia.
Topics: Aspirin; Female; Fetal Growth Retardation; Gestational Age; Humans; Longitudinal Studies; Platelet A | 1993 |
The lupus anticoagulant and pregnancy.
Topics: Adult; Aspirin; Female; Humans; Lupus Coagulation Inhibitor; Prednisone; Pregnancy; Pregnancy Compli | 1993 |
Primary thrombocythemia and pregnancy: treatment and outcome in fifteen cases.
Topics: Adult; Aspirin; Female; Fibrinogen; Fibrinolytic Agents; Gestational Age; Hemoglobins; Heparin; Huma | 1996 |
Thrombotic thrombocytopenic purpura in pregnancy.
Topics: Aspirin; Female; Humans; Plasma Exchange; Pregnancy; Pregnancy Complications, Hematologic; Purpura, | 1996 |
[Essential thrombocythemia in pregnancy. A case report and general considerations].
Topics: Adult; Aspirin; Drug Therapy, Combination; Female; Humans; Hydroxyurea; Infant, Newborn; Male; Plate | 1997 |
Postpartum thrombosis in primary thrombocythaemia.
Topics: Adult; Aspirin; Female; Humans; Pregnancy; Pregnancy Complications, Hematologic; Thrombocytosis; Thr | 1997 |
Pregnancy in a patient with essential thrombocytosis.
Topics: Aspirin; Female; Humans; Ischemia; Placenta; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy C | 1997 |
Pregnancy-related death associated with heparin and aspirin treatment for infertility, 1996.
Topics: Adult; Anticoagulants; Aspirin; Cerebral Hemorrhage; Fatal Outcome; Female; Fertilization in Vitro; | 1998 |
From the Centers for Disease Control and Prevention. Pregnancy-related death associated with heparin and aspirin treatment for infertility, 1996.
Topics: Adult; Anticoagulants; Aspirin; Cerebral Hemorrhage; Fatal Outcome; Female; Fertilization in Vitro; | 1998 |
Low-molecular-weight heparin combined with aspirin in pregnant women with thrombophilia and a history of preeclampsia or fetal growth restriction: a preliminary study.
Topics: Aspirin; Drug Therapy, Combination; Female; Fetal Growth Retardation; Gestational Age; Heparin, Low- | 1998 |
Successful pregnancies after recurrent abortions in mild essential thrombocythemia.
Topics: Abortion, Habitual; Adult; Aspirin; Busulfan; Female; Humans; Platelet Aggregation Inhibitors; Pregn | 1998 |
Low-risk essential thrombocythaemia in patients younger than 40.
Topics: Adolescent; Adult; Aspirin; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Male; | 1999 |
Essential thrombocythemia in young adults: treatment and outcome of 16 pregnancies.
Topics: Adult; Aspirin; Female; Humans; Platelet Aggregation Inhibitors; Pregnancy; Pregnancy Complications, | 1999 |
High-risk pregnancy in beta-thalassemia major women. Report of three cases.
Topics: Adult; Aspirin; beta-Thalassemia; Cardiomyopathy, Dilated; Deferoxamine; Female; Humans; Pregnancy; | 2000 |
Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
Topics: Acute Disease; Adult; Age Factors; Arteriosclerosis; Aspirin; Busulfan; Cohort Studies; Disease-Free | 2000 |
The effect of thrombophylaxis on pregnancy outcome in patients with recurrent pregnancy loss associated with factor V Leiden mutation.
Topics: Abortion, Habitual; Adult; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Factor V; | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Thromboembolic prophylaxis with danaparoïd (Orgaran) in a high-thrombosis-risk pregnant woman with a history of heparin-induced thrombocytopenia (HIT) and Widal's disease.
Topics: Adult; Anticoagulants; Aspirin; Asthma; Cephalosporins; Chondroitin Sulfates; Dermatan Sulfate; Drug | 2000 |
Non-pregnant circulatory volume status predicts subsequent pregnancy outcome in normotensive thrombophilic formerly preeclamptic women.
Topics: Aspirin; Birth Weight; Female; Fetal Growth Retardation; Folic Acid; Gestational Age; HELLP Syndrome | 2001 |
May-hegglin anomaly: the role of aspirin in the treatment of this rare platelet disorder in pregnancy.
Topics: Adult; Aspirin; Female; Humans; Inclusion Bodies; Platelet Aggregation Inhibitors; Pregnancy; Pregna | 2002 |
Danaparoid thromboprophylaxis in pregnant women with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Antithrombin III; Aspirin; Chondroitin Sulfates; Dermatan Sulfate; Drug Combi | 2002 |
Four pregnancies in two patients with essential thrombocythaemia--a case report.
Topics: Adult; Aspirin; Combined Modality Therapy; Cyclooxygenase Inhibitors; Female; Fetal Death; Humans; H | 2002 |
Disseminated intravascular coagulation induced by progesterone in the pregnant rat. Prevention by estogens.
Topics: Animals; Aspirin; Cortisone; Dicumarol; Diet; Disseminated Intravascular Coagulation; Estrogens; Fem | 1977 |
[Effects of aspirin on pregnant women and fetus; tetracycline-induced esophageal ulcer; and re-evaluation of sulfa drugs, anti-inflammatory enzymes and vitamins].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anemia; Anti-Inflammatory Agents; Aspirin; Esophagea | 1977 |
Vascular responsiveness to pressor agents during human pregnancy.
Topics: Aldosterone; Angiotensin II; Aspirin; Female; Hematocrit; Humans; Hypertension; Indomethacin; Pregna | 1979 |
Survival following thrombotic thrombocytopenic purpura in pregnancy.
Topics: Adult; Aspirin; Blood Coagulation Tests; Blood Transfusion; Blood Urea Nitrogen; Cesarean Section; D | 1977 |
The prevention of acute pulmonary embolism.
Topics: Adult; Anticoagulants; Aspirin; Dextrans; Early Ambulation; Female; Heparin; Humans; Leg; Postoperat | 1977 |
[Pregnancy, heart valve prostheses and anti-platelet aggregation treatment].
Topics: Adult; Anticoagulants; Aspirin; Dipyridamole; Drug Combinations; Female; Heart Valve Prosthesis; Hum | 1975 |
Essential thrombocythemia in pregnancy: platelet count and pregnancy outcome.
Topics: Adult; Aspirin; Female; Humans; Platelet Count; Pregnancy; Pregnancy Complications, Hematologic; Pre | 1992 |
Prospective modulation of platelet function and volumes by aspirin and dipyridamole in an at-risk pregnancy.
Topics: Adult; Aspirin; Blood Platelets; Dipyridamole; Female; Humans; Platelet Aggregation; Platelet Count; | 1992 |
Thrombotic thrombocytopenic purpura in early pregnancy with maternal and fetal survival.
Topics: Adult; Aspirin; Biomarkers; Dipyridamole; Female; Humans; Infant, Newborn; L-Lactate Dehydrogenase; | 1992 |
Role of thrombelastography in bleeding diatheses and regional anaesthesia.
Topics: Adult; Anesthesia, Conduction; Aspirin; Female; Hemorrhagic Disorders; Humans; Male; Middle Aged; Pr | 1991 |
Low-dose aspirin and nulliparae.
Topics: Aspirin; Female; Humans; Hypertension; Parity; Pre-Eclampsia; Pregnancy; Pregnancy Complications; Pr | 1991 |
Thrombelastography in pregnant patients on low-dose aspirin.
Topics: Aspirin; Blood Coagulation Disorders; Female; Humans; Pregnancy; Pregnancy Complications, Hematologi | 1991 |
Idiopathic thrombocythemia and pregnancy; a case report.
Topics: Adult; Aspirin; Female; Humans; Melphalan; Pregnancy; Pregnancy Complications, Hematologic; Thromboc | 1991 |
Essential thrombocythemia and complications of pregnancy.
Topics: Abortion, Incomplete; Aspirin; Female; Fetal Death; Humans; Pregnancy; Pregnancy Complications, Hema | 1991 |
Prolongation of premature gestation in women with hemolysis, elevated liver enzymes and low platelets. A report of five cases.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Female; Hemolysis; Humans; Hypertension; Liver; Pregnancy; | 1990 |
Thromboembolic disease during pregnancy: problems with anticoagulant therapy.
Topics: Anticoagulants; Aspirin; Blood Coagulation Factors; Female; Fibrinolysis; Heart Valve Prosthesis; He | 1990 |
Successful pregnancies of two patients with relapsing thrombotic thrombocytopenic purpura.
Topics: Adult; Aspirin; Blood Transfusion; Combined Modality Therapy; Dipyridamole; Drug Therapy, Combinatio | 1989 |
[Multiple fetal losses caused by a circulating anticoagulant. Correction with a combination of aspirin and corticotherapy].
Topics: Abortion, Habitual; Adult; Aspirin; Blood Coagulation; Female; Humans; Immunoglobulins; Prednisolone | 1986 |
Thrombocytopenia associated with pregnancy in a patient with type IIB von Willebrand's disease.
Topics: Adult; Aspirin; Blood Coagulation Tests; Bucladesine; Epoprostenol; Female; Humans; Platelet Aggrega | 1987 |
Bleeding.
Topics: Aspirin; Blood Coagulation Disorders; Blood Platelet Disorders; Female; Hemorrhage; Hemostasis; Huma | 1987 |
Successful pregnancy after pharmacologic suppression of a circulating anticoagulant in a woman with previous pregnancy losses and pulmonary emboli. A case report.
Topics: Adult; Aspirin; Blood Coagulation; Female; Humans; Immunoglobulins; Infant, Newborn; Partial Thrombo | 1987 |
Essential thrombocythemia associated with recurrent abortions and fetal growth retardation.
Topics: Abortion, Habitual; Adult; Aspirin; Dipyridamole; Female; Fetal Growth Retardation; Humans; Platelet | 1987 |
Idiopathic thrombocythemia and pregnancy: report of a case.
Topics: Adult; Aspirin; Female; Hematologic Tests; Humans; Platelet Count; Postpartum Period; Pregnancy; Pre | 1985 |
Thrombotic thrombocytopenic purpura in early pregnancy.
Topics: Adult; Aspirin; Combined Modality Therapy; Dipyridamole; Female; Gestational Age; Hematocrit; Humans | 1985 |
Role of antihistaminics in preventing systemic side effects of iron-dextran therapy.
Topics: Anemia, Hypochromic; Aspirin; Chlorpheniramine; Female; Histamine H1 Antagonists; Humans; Iron-Dextr | 1970 |
Treatment of sickle-cell disease.
Topics: Anemia, Sickle Cell; Anesthesia; Anticoagulants; Aspirin; Bicarbonates; Blood; Blood Flow Velocity; | 1974 |
[Hemolytic-uremic syndrome and microangiopathic hemolytic anemia].
Topics: Adrenal Cortex Hormones; Anemia, Hemolytic; Aspirin; Dextrans; Dipyridamole; Drug Hypersensitivity; | 1973 |